Edesa Biotech (EDSA) announced the appointment of Peter Weiler as CFO, effective May 1. Weiler will succeed Stephen Lemieux, who will be stepping down from the role effective May 1, to pursue other professional opportunities. Weiler brings extensive experience in finance and corporate strategy within the biotechnology and pharmaceutical industries. Since August 2018, Weiler served as President of Exzell Pharma, a privately held, commercial-stage pharmaceutical company.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EDSA:
- Edesa Biotech files to sell 7.81M common shares for holders
- Edesa Biotech Advances Vitiligo Treatment Amidst Solid Financial Backing
- Edesa Biotech announces $15M private placement priced at-the-market
- Edesa Biotech Secures $15 Million in Private Placement to Advance Clinical Programs
- Edesa Biotech Secures $15 Million for CXCL10 Antibody Program
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue